Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers.

Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Abstract Text:

    louise h williamsLouise H Williams,david choongDavid Choong,sandra a johnsonSandra A Johnson,ian g campbellIan G Campbell,

    PURPOSE: Germ-line variants in CHEK2 have been associated with increased breast, thyroid, prostate, kidney, and colorectal cancer risk; however, the prevalence of somatic inactivation of CHEK2 in common cancer types is less clear. The aim of this study was to determine if somatic mutation and/or epigenetic modification play a role in development of sporadic breast, colon, or ovarian cancers. EXPERIMENTAL DESIGN: We undertook combined genetic and epigenetic analysis of CHEK2 in sporadic primary breast, ovarian, and colon tumors [all exhibiting chromosome 22q loss of heterozygosity (LOH)] and cancer cell lines. Expression of Chk2 was assessed by immunohistochemistry in 119 ovarian tumors. RESULTS: Two novel germ-line variants were identified; however, none of the primary tumors harbored somatic mutations. Two CpG clusters previously implicated in CHEK2 silencing were investigated for evidence of hypermethylation. No methylation was detected at the distal CpG island. The proximal CpG cluster was methylated in all tumor and normal DNA, suggesting that this might not represent a true CpG island and is not relevant in the control of CHEK2 expression. Twenty-three percent of ovarian tumors were negative for Chk2 protein by immunohistochemistry, but there was no significant correlation between LOH across the CHEK2 locus and intensity of Chk2 staining (P = 0.12). CONCLUSIONS: LOH across the CHEK2 locus is common in sporadic breast, ovarian, and colorectal cancers, but point mutation or epigenetic inactivation of the retained allele is uncommon. Loss of Chk2 protein in ovarian cancer was not associated with allelic status, suggesting that inactivation does not occur as a consequence of haploinsufficiency.

    Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Publishing Authors By Initials

    lh williamsLH Williams,d choongD Choong,sa johnsonSA Johnson,ig campbellIG Campbell,

    For similar genetic phenomena: variation (genetics) research abstracts see: genetic phenomena: variation (genetics) research

    PUBMED ID PMID:

    MEDLINE DATE:

    Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Clinical cancer research : an official journal of

    VOLUME: 12

    Page Numbers: 6967-72

    Journal Abbreviation: Clin. Cancer Res.

    ISSN: 1078-0432

    DAY: 1

    MONTH: Dec

    YEAR: 2006

    Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9502500

    Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Keywords Mesh Terms:

    KEYWORDS: Variation (Genetics)

    MESH TERMS: genetics

    Chemical & Substance for Abstract: Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Information

    Substance Name: Protein-Serine-Threonine Kinases

    Registry Number: EC 2.7.11.1

    Grant and Affiliation Information for Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers.

    AFFILIATION: Victorian Breast Cancer Research Consortium Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Clin Cancer Res

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News